Stock Events

Emergent Biosolutions 

€10.77
94
+€0.6+5.9% Friday 16:31

Statistics

Day High
10.77
Day Low
9.85
52W High
-
52W Low
-
Volume
10,750
Avg. Volume
-
Mkt Cap
558.08M
P/E Ratio
-0.98
Dividend Yield
-
Dividend
-

Earnings

7MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-3.17
-2.09
-1.01
0.07
Expected EPS
-0.83
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ER4.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap163.88B
Pfizer competes in the biopharmaceutical sector, developing vaccines and therapeutics similar to Emergent Biosolutions' portfolio.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines and drugs that directly compete with Emergent's offerings.
Merck &
MRK
Mkt Cap323.59B
Merck & Co. is involved in the creation of vaccines and therapeutic drugs, competing in the same space as Emergent Biosolutions.
GSK
GSK
Mkt Cap81.16B
GlaxoSmithKline focuses on vaccines and pharmaceuticals, making it a direct competitor in Emergent Biosolutions' market.
Sanofi
SNY
Mkt Cap130B
Sanofi operates in the pharmaceutical and vaccines market, directly competing with Emergent Biosolutions in several areas.
BioNTech
BNTX
Mkt Cap20.19B
BioNTech SE partners with Pfizer on vaccine development, directly competing with Emergent Biosolutions in the vaccine space.
Novavax
NVAX
Mkt Cap1.84B
Novavax is a direct competitor in the vaccine development sector, particularly in the development of COVID-19 vaccines.
Abbott Laboratories
ABT
Mkt Cap181.3B
Abbott Laboratories competes with Emergent Biosolutions in the diagnostics and medical devices sector, indirectly competing in the broader healthcare market.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca competes in the development of vaccines, including COVID-19 vaccines, positioning it as a competitor to Emergent Biosolutions.
Modine Manufacturing
MOD
Mkt Cap5.65B
Moderna is a key competitor in the mRNA vaccine space, directly competing with Emergent Biosolutions in COVID-19 vaccine development and beyond.

Analyst Ratings

8Average Price Target
The highest estimate is €8.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Mr. Richard S. Lindahl M.B.A.
Employees
1600
Country
US
ISIN
US29089Q1058
WKN
000A0LC2W

Listings